Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction

Blood

Volumn 114, Issue 19, 2009, Pages 4045-4053

  Chen, Michael L ^a   Logan, T Daniel ^a   Hochberg, Maryann L ^b   Shelat, Suresh G ^c   Yu, Xiang ^c   Wilding, Gregory E ^b,d   Tan, Wei ^b   Kujoth, Gregory C ^e   Prolla, Tomas A ^e   Selak, Mary A ^c   Kundu, Mondira ^f   Carroll, Martin ^a   Thompson, James E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMIDINE;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW TRANSPLANTATION; CELL MATURATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSPLASIA; ERYTHROID CELL; ERYTHROID DYSPLASIA; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LYMPHOPOIESIS; MACROCYTIC ANEMIA; MEGALOBLASTIC ANEMIA; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REFRACTORY ANEMIA;

EID: 77950236668     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-169474     Document Type: Article

References (49)

1. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-4851.
2. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281(5381):1309-1312.
3. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35(11):1739-1746.
4. Cazzola M, Barosi G, Gobbi P, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood. 1988;71(2):305-312.
5. Pearson HA, Lobel JS, Kocoshis SA, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr. 1979;95(6):976-984.
6. Rötig A, Cormier V, Blanche S, et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest. 1990;86(5):1601-1608.
7. Yunis AA, Smith US, Restrepo A. Reversible bone marrow suppression from chloramphenicol. A consequence of mitochondrial injury. Arch Intern Med. 1970;126(2):272-275.
8. Dawson MA, Davis A, Elliott P, Cole-Sinclair M. Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited. Intern Med J. 2005;35(10):626-628.
9. Löffler M, Jockel J, Schuster G, Becker C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem. 1997;174(1-2):125-129.
10. Chinnery PF, Samuels DC. Relaxed replication of mtDNA: a model with implications for the expression of disease. Am J Hum Genet. 1999;64(4):1158- 1165.
11. Larsson NG, Clayton DA. Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet. 1995;29:151-178.
12. Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood. 1997;90(12):4961-4972.
13. Gattermann N, Wulfert M, Junge B, Germing U, Haas R, Hofhaus G. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. Blood. 2004;103(4):1499-1502.
14. Reddy PL, Shetty V, Dutt D, et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol. 2002;116(3):564-575.
15. Shin MG, Kajigaya S, Levin BC, Young NS. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood. 2003;101(8):3118-3125.
16. Wulfert M, Küpper AC, Tapprich C, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol. 2008;36(5):577-586.
17. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 2004;429(6990):417- 423.
18. Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science. 2005;309(5733):481-484.
19. Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest. 2004;114(10):1457-1466.
20. Spangrude GJ, Brooks DM, Tumas DB. Longterm repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood. 1995;85(4):1006-1016.
21. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M. Suppression of fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood. 2006;108(1):123-133.
22. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for {beta}0-thalassemia. Proc Natl Acad Sci U S A. 1995;92(25):11608-11612.
23. Socolovsky M. Molecular insights into stress erythropoiesis. Curr Opin Hematol. 2007;14(3):215-224.
24. Socolovsky M, Nam H, Fleming M, Haase V, Brugnara C, Lodish H. Ineffective erythropoiesis in Stat5a-/-5b-/- mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.
25. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-2268.
26. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82(2):358-367.
27. Rådlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995;54(3):153-156.
28. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
29. NIEHS - Mitochondrial DNA Replication Group. Human DNA polymerase gamma mutation database. http://tools.niehs.nih.gov/polg/. Accessed July 2, 2008.
30. Wong LC, Naviaux RK, Brunetti-Pierri N, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat. 2008;29(9):E150-E172.
31. McKusick VA, Rosooly RS, Hamosh A, et al. OMIM: Polymerase, DNA, gamma; POLG. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=174763. Accessed November 29, 2008.
32. Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21(4):668-677.
33. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (lowrisk) myelodysplastic syndrome. Blood. 2005;106(9):2982-2991.
34. + cells in low-grade myelodysplastic syndromes. Blood. 2006;108(3):1037-1044.
35. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VHJ, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111(3):1067-1077.
36. Amin HM, Jilani I, Estey EH, et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003;102(5):1866-1868.
37. Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol. 2002;119(1):97-105.
38. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245.
39. Parry TE. On the pathogenesis of erythroleukaemia (H0493). Leuk Res. 2005;29(2):119-121.
40. Queisser W, Pepperl U, Kempgens U, Muller U. Characterization of ineffective erythropoiesis in erythroleukaemia. Acta Haematol. 1975;54(2):65-74.
41. Riddell EM, Davidson RJL. Coexistence of pernicious anaemia and acute erythraemic myelosis. J Clin Pathol. 1968;21(5):590-594.
42. Drabick JJ, Davis BJ, Byrd JC. Concurrent pernicious anemia and myelodysplastic syndrome. Ann Hematol. 2001;80(4):243-245.
43. Boss GR. Cobalamin inactivation decreases purine and methionine synthesis in cultured lymphoblasts. J Clin Invest. 1985;76(1):213-218.
44. van der Weyden MB, Hayman RJ, Rose IS, Brumley J. Folate-deficient human lymphoblasts: changes in deoxynucleotide metabolism and thymidylate cycle activities. Eur J Haematol. 1991;47:109.
45. Koury MJ, Price JO, Hicks GG. Apoptosis in megaloblastic anemia occurs during DNA synthesis by a p53-independent, nucleoside-reversible mechanism. Blood. 2000;96(9):3249-3255.
46. Gattermann N, Dadak M, Hofhaus G, et al. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1275-1279.
47. Toyokawa Y, Kingetsu I, Yasuda C, et al. Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. Mod Rheumatol. 2007;17(5):436-440.
48. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93(3):198-208.
49. Mufti GJ, Galton DA. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin Haematol. 1986;15(4):953-971.